In addition, evaluation of the expression level of PPARγ and its subcellular localization in early-stage breast tumors should be considered a tailored selection criteria for patients to develop more effective translational and precision medicine strategies for breast cancer patients. The gene discussed is PPARG; the disease is breast carcinoma.